What does the endocrine system do?
The endocrine system includes major glands such as the thyroid, pituitary, adrenal glands and pancreas. NIDDK describes its effects on growth, development, metabolism, sexual function and mood. Endocrine disorders can involve hormone levels that are too high or too low, or a body response to hormones that does not work as expected. Hormone health is therefore broader than raising a single hormone level. NIDDK endocrine-system overview.
A hormone, a hormone analogue and a receptor agonist are different descriptions
Testosterone is an androgen hormone. NCI describes nandrolone as a synthetic anabolic steroid analogue of testosterone. Semaglutide acts as a GLP-1 receptor agonist, while tirzepatide acts at GIP and GLP-1 receptors. Those names describe different biological and pharmacological relationships; they are not interchangeable labels for one kind of treatment. AndroGel 1.62% prescribing information, NCI nandrolone definition, WEGOVY prescribing information, ZEPBOUND prescribing information.
IGF-1 is a hormonal mediator of statural growth. Mecasermin is human IGF-1 made using recombinant DNA technology, and the INCRELEX label says it is not a substitute for growth hormone for approved growth-hormone indications. A connection between growth-related systems does not make the medicines interchangeable. INCRELEX prescribing information.
Testosterone replacement has a defined patient indication
The US AndroGel 1.62% label indicates replacement therapy for males with deficiency or absence of endogenous testosterone associated with primary or hypogonadotropic hypogonadism. This is different from a general claim about performance or hormone optimization. FDA also reported blood-pressure increases across testosterone products in completed ambulatory studies and required related warning information. The testosterone guide covers this topic in more detail. AndroGel 1.62% prescribing information, FDA testosterone blood-pressure warning update.
Weight management: semaglutide and tirzepatide
The US WEGOVY injection indication for long-term weight reduction covers adults and pediatric patients aged 12 years or older with obesity, or adults with overweight and at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity. ZEPBOUND's US long-term weight-reduction indication covers adults with obesity, or adults with overweight and at least one weight-related comorbid condition, with the same diet-and-activity conditions. WEGOVY prescribing information, ZEPBOUND prescribing information.
In the named products' adult weight-management trials, nausea, diarrhea, vomiting, constipation and abdominal pain were among adverse reactions reported in at least 2% of treated participants and more often than with placebo. These are separate trial records, not a direct comparison of event rates. Both labels contraindicate the medicine with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Read semaglutide, tirzepatide or their comparison. WEGOVY prescribing information, ZEPBOUND prescribing information.
IGF-1: a pediatric growth-failure indication and low-glucose risk
The US INCRELEX indication is treatment of growth failure in pediatric patients aged 2 years or older with severe primary IGF-1 deficiency, or growth hormone gene deletion with neutralizing antibodies to growth hormone. Severe hypoglycemia leading to hypoglycemic seizures has been observed with INCRELEX treatment. These are specific indication and safety details, rather than a general adult growth or longevity benefit. The IGF-1 guide explains the reference medicine. INCRELEX prescribing information.
Research compounds: a hormone change is not automatically a health improvement
In the 2008 placebo-controlled MK-677 study of 65 healthy adults aged 60 to 81, fat-free mass increased without an observed improvement in strength or function. Fasting glucose increased and insulin sensitivity decreased. A change in a body-composition measure therefore did not, in that study, amount to better function or an uncomplicated metabolic benefit. See the MK-677 guide. MK-677 randomized older-adult study.
A randomized GHRP-2 experiment in 19 healthy, weight-stable adults measured acute food intake and growth-hormone responses during short infusions. Food intake and GH increased, but the experiment did not evaluate long-term muscle or fat outcomes. The GHRP-2 guide is a separate research topic from a medicine's approved indication. GHRP-2 appetite and hormone study.
How do the evidence questions differ?
An endocrine disorder may concern hormone amount or hormone response. A medicine label names a product and a patient group, such as testosterone replacement in specified hypogonadism or INCRELEX in specified pediatric growth failure. A research experiment may instead measure an acute hormone response or a body-composition endpoint. Keeping those questions distinct makes a claim easier to assess without mistaking every laboratory change for a demonstrated health benefit. NIDDK endocrine-system overview, AndroGel 1.62% prescribing information, INCRELEX prescribing information, GHRP-2 appetite and hormone study, MK-677 randomized older-adult study.
